Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02881749|
Recruitment Status : Unknown
Verified August 2016 by Thomas Jefferson University.
Recruitment status was: Not yet recruiting
First Posted : August 29, 2016
Last Update Posted : August 30, 2016
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Mycosis Fungoides Cutaneous T-cell Lymphoma||Radiation: Total skin electron beam therapy (TSEBT) Drug: mechlorethamine gel 0.016%||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||68 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||August 2020|
Experimental: TSEBT & mechlorethamine gel 0.016%
All subjects enrolled in the study will receive two weeks of low dose total skin electron beam therapy (TSEBT) (12 Gy total divided into 6 fractions delivered over two weeks) followed by a weekly maintenance mechlorethamine gel 0.016% regimen for one year. The initiation of the mechlorethamine gel regimen is dependent on their disease stage downgrading to IA and IB following low dose TSEBT.
Radiation: Total skin electron beam therapy (TSEBT)
TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other "shadowed" sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional "boost" up to 8 Gy.
Drug: mechlorethamine gel 0.016%
The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
Other Name: Valchlor
- Time to progression [ Time Frame: One year ]To assess the time to progression of patients treated with total skin electron beam therapy (TSEBT) followed by the year-long maintenance Valchlor regimen.
- Response rate (CR and PR) [ Time Frame: One year ]To assess the response rate (CR and PR) of patients treated with total skin electron beam therapy (TSEBT) followed by the year-long maintenance Valchlor regimen. . CR and PR are defined as the standard oncology criteria for complete response (100% reduction from the baseline score) and partial response (50% to <100% reduction from the baseline score).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- 1. Male or Female
- ≥ 18 years of age
- Documentation of diagnosis as evidenced by one or more clinical features consistent with Mycosis Fungoides cutaneous T-Cell lymphoma
- Written informed consent obtained from subject or subject's legal representative and ability for subject to comply with requirements of the study
- Skin biopsy specimen of representative lesion obtained at screening of study and deemed diagnostic of Mycosis Fungoides by principal investigator
- Eligible, in the opinion of the investigator, for low dose TSEBT over the course of two weeks.
- Availability of subject to be observed for up to 18 months post-screening evaluation.
- Life Expectancy greater than 6 months
- Pregnant or breast-feeding females
- Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data
- Patients diagnosed with Sezary Syndrome. Sezary Syndrome is equivalent to mycosis fungoides that develops to Stage IVA/B with B2 (high blood tumor burden) involvement, and as such requires a more aggressive treatment regimen than Valchlor or TSEBT.
- Patients who do not have their disease downgrade to stage IA or IB 30 days following low dose TSEBT.
- Underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the patient to undergo treatment
- Minimum 3 weeks since prior systematic treatment or phototherapy
- Decisionally-impaired individuals, prisoners, and vulnerable populations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02881749
|Contact: Kelly Knoblauch||(215) email@example.com|
|Responsible Party:||Thomas Jefferson University|
|Other Study ID Numbers:||
|First Posted:||August 29, 2016 Key Record Dates|
|Last Update Posted:||August 30, 2016|
|Last Verified:||August 2016|
Lymphoma, T-Cell, Cutaneous
Neoplasms by Histologic Type
Immune System Diseases
Bacterial Infections and Mycoses
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating